ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.)

ADVMのニュース

   Stock Analysts’ Upgrades for November, 12th (ACAD, ADVM, AOBC, ATSG, BIDU, CLLS, DXPE, FEYE, FHB, FSBW)  2019/11/12 15:58:09 Modern Readers
Stock Analysts’ upgrades for Tuesday, November 12th: ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at BidaskClub from a sell rating to a hold rating. Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. American Outdoor Brands (NASDAQ:AOBC) was upgraded by analysts at BidaskClub from a buy rating […]
   Adverum Biotechnologies Enters Oversold Territory  2019/09/30 13:04:00 Zacks Investment Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why  2019/09/25 13:00:07 Zacks Investment Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Adverum Reports Data From Phase I Wet AMD Study, Stock Down  2019/09/13 14:06:00 Zacks Investment Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
   Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial  2019/09/12 15:30:37 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing on ocular and rare diseases, announced 24-week, Phase 1 clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 for wet age-related macular degeneration, or wet AMD. The actively traded, small-cap biotech said the patients achieved vision maintenance and improvements in retinal anatomy after a one-time intravitreal dose of ADVM-022 through week 24. More importantly, … Full story available on Benzinga.com
  11月12日の株式アナリストのアップグレード(ACAD、ADVM、AOBC、ATSG、BIDU、CLLS、DXPE、FEYE、FHB、FSBW)」 Stock Analysts’ Upgrades for November, 12th (ACAD, ADVM, AOBC, ATSG, BIDU, CLLS, DXPE, FEYE, FHB, FSBW)  2019/11/12 15:58:09 Modern Readers
「11月12日火曜日のストックアナリストのアップグレード:ACADIA Pharmaceuticals(NASDAQ:ACAD)は、BidaskClubのアナリストによって売り評価からホールド評価にアップグレードされました。AdverumBiotechnologies(NASDAQ:ADVM)は、BidaskClubのアナリストによってホールド評価からアップグレードされましたAmerican Outdoor Brands(NASDAQ:AOBC)は、BidaskClubのアナリストによって購入評価からアップグレードされました[…]
Stock Analysts’ upgrades for Tuesday, November 12th: ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at BidaskClub from a sell rating to a hold rating. Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. American Outdoor Brands (NASDAQ:AOBC) was upgraded by analysts at BidaskClub from a buy rating […]
   Adverum Biotechnologies Enters Oversold Territory  2019/09/30 13:04:00 Zacks Investment Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why  2019/09/25 13:00:07 Zacks Investment Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Adverum Reports Data From Phase I Wet AMD Study, Stock Down  2019/09/13 14:06:00 Zacks Investment Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
   Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial  2019/09/12 15:30:37 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing on ocular and rare diseases, announced 24-week, Phase 1 clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 for wet age-related macular degeneration, or wet AMD. The actively traded, small-cap biotech said the patients achieved vision maintenance and improvements in retinal anatomy after a one-time intravitreal dose of ADVM-022 through week 24. More importantly, … Full story available on Benzinga.com
   The Best-Performing Small-Cap Stocks YTD: May 2019  2019-05-16
The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am…
   Microcaps mostly among midday movers  2019-05-16
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D…
   Adverum up 16% on advancement of ADVM-022 in early-stage wet AMD study  2019-05-16
Adverum Biotechnologies ( ADVM +16% ) is up on almost 20% higher volume in response to its announcement that the FDA has lifted the clinical hold on the second cohort in a Phase 1 study, OPTIC , evaluating lead gene therapy ADVM-022 (AAV.7m8-aflibercept) in patients with wet age-rel…

calendar